IC
APLT

Ikarian Capital’s Applied Therapeutics APLT Stock Holding History

Ikarian Capital’s Portfolio APLT Stock Details APLT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-200,000
Closed -$4.4M – 297
2020
Q4 		$4.4M Buy
+200,000
New +$4.16M 0.19% 102

Other funds holding APLT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
EMFAT
Emerald Mutual Fund Advisers Trust Leola, Pennsylvania $2.06B AUM 106.87% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

Ikarian Capital's APLT Position: Q1 2021 in Review

Ikarian Capital sold out of Applied Therapeutics (APLT) in Q1 2021, closing a stake of 33,002 shares — an estimated $726K sold.

Ikarian Capital first reported a position in APLT in Q4 2020 and held it in 1 quarter. The position peaked at $726K in Q4 2020. 67 funds tracked by Wall St. Rank hold APLT as of Q1 2021.

  • Ikarian Capital reported no remaining Applied Therapeutics position as of Q1 2021 after selling out during the quarter.
  • Ikarian Capital sold 33,002 Applied Therapeutics shares in Q1 2021, an estimated $726K.
  • Ikarian Capital first reported a position in Applied Therapeutics in Q4 2020 and held it in 1 quarter.
  • Ikarian Capital's Applied Therapeutics position peaked at $726K in Q4 2020.
  • 67 funds tracked by Wall St. Rank held Applied Therapeutics as of Q1 2021.

Based on Ikarian Capital's 13F filing for Q1 2021, filed 17 May 2021.